Notably, rosuvastatin consistently demonstrated superior efficacy in modulating the Bax/Bcl-2 axis across both colorectal cancer cell lines, achieving greater pro-apoptotic shifts at lower concentrations than atorvastatin. Here, BCL2 is linked to colorectal cancer.